Avidity Biosciences, INC Form 4 insider transactions

Avidity Biosciences' Chief Financial Officer, Michael F. MacLean, acquired 25,000 restricted stock units and 50,000 stock options on January 6, 2025.

Avidity Biosciences CEO, Sarah Boyce, acquired 82,500 shares of restricted stock units and 165,000 stock options on January 6, 2025.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, acquired 25,000 restricted stock units and 50,000 stock options on January 6, 2025.

Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences, acquired 25,000 shares of common stock and 50,000 stock options on January 6, 2025.

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, acquired 25,000 shares of restricted stock units and options for 50,000 shares on January 6, 2025.

Avidity Biosciences' Chief Technical Officer, Charles Calderaro III, acquired 40,000 shares of common stock and 80,000 stock options on January 6, 2025.

Avidity Biosciences' Chief Scientific and Technology Officer, W. Michael Flanagan, sold 12,742 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Avidity Biosciences' Chief Financial Officer, Michael F. MacLean, sold 11,151 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Avidity Biosciences CEO, Sarah Boyce, sold 31,855 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, sold 11,151 shares to cover tax obligations following the vesting of restricted stock units.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Avidity Biosciences' Chief Scientific and Technology Officer, W. Michael Flanagan, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, exercised stock options and sold 25,000 shares of common stock on November 18, 2024, under a pre-arranged trading plan.

Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences, Inc. on November 19, 2024, according to a recent SEC filing.

Michael F. MacLean, CFO of Avidity Biosciences, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences (RNA) on October 21, 2024, according to a Form 4 filing.

Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, exercised stock options and sold 25,000 shares of common stock on October 16, 2024, under a pre-arranged trading plan.

Director Tamar Thompson exercised stock options and sold 30,000 shares of Avidity Biosciences (RNA) common stock on October 7, 2024.

W. Michael Flanagan, CSTO of Avidity Biosciences, exercised stock options and sold 62,500 shares of common stock on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Chief Human Resources Officer Teresa McCarthy reports acquisition and disposal of Avidity Biosciences stock related to performance-based restricted stock units (PSUs) vesting.

W. Michael Flanagan, CSTO of Avidity Biosciences, sold shares to cover tax obligations after performance-based restricted stock units vested due to the achievement of a clinical milestone.

Avidity Biosciences CEO Sarah Boyce reports acquisition and disposal of company stock related to the vesting of performance-based restricted stock units (PSUs) and subsequent sell-to-cover transactions.

Avidity Biosciences' CFO, Michael MacLean, reports acquisition and disposal of company stock related to the vesting of performance-based restricted stock units (PSUs) and subsequent sell-to-cover transactions.

Director Arthur Levin exercised stock options and sold shares of Avidity Biosciences (RNA) on September 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

W. Michael Flanagan, CSTO of Avidity Biosciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, exercised stock options and sold 25,000 shares of common stock at an average price of $40.4017, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Director Arthur A. Levin reports gifting shares of Avidity Biosciences stock to family and charitable remainder trusts.

Director Arthur Levin exercised stock options and sold shares of Avidity Biosciences (RNA) on August 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Avidity Biosciences' CEO, Sarah Boyce, exercised stock options and sold shares on August 6, 2024, according to a Form 4 filing with the SEC.

John B. Moriarty, Chief Legal Officer of Avidity Biosciences, acquired 25,000 shares of common stock and stock options for 160,000 shares on August 1, 2024, as reported in a Form 4 filing with the SEC.